Assertio Stock Up 36.4% YTD with 6.6% Earnings Estimate Boost
Assertio shares have surged 36.4% year-to-date, outpacing the Medical sector's 1.9% gain and the Medical-Drugs industry's 1.5% rise. Analysts have lifted ASRT's full-year earnings estimate by 6.6% in the past quarter and assigned it a Zacks Rank #2 (Buy).
1. ASRT Year-to-Date Outperformance
Assertio stock has climbed 36.4% since January 1, significantly exceeding the Medical sector's 1.9% average return and the Medical-Drugs industry's 1.5% gain.
2. Upgraded Earnings Outlook and Zacks Rank
Analysts increased Assertio's full-year earnings consensus by 6.6% over the past quarter, reflecting stronger profit expectations, and the stock carries a Zacks Rank #2 (Buy) designation.
3. Industry Rankings and Peer Comparisons
Assertio is part of the Medical sector (ranked 11th of 16 groups) and the Medical-Drugs industry, which comprises 140 stocks but ranks 143rd among all industries and has gained 1.5% YTD. Peer Aura Biosciences has risen 2.2% YTD, seen a 5.9% EPS estimate increase and holds a Zacks Rank #2.